Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lanifibranor
- Development stage
- Phase 3
- Lead developer
- Inventiva
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lanifibranor is an orally available small molecule drug developed by Inventiva for the treatment of metabolic and fibrotic diseases, most notably non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatotic liver disease (MASLD). It is a pan-peroxisome proliferator–activated receptor (pan-PPAR) agonist, meaning it activates all three PPAR isoforms—PPAR-alpha, PPAR-delta, and PPAR-gamma. This balanced activation leads to anti-fibrotic, anti-inflammatory, vascular protective, and beneficial metabolic effects that are not achievable with single or dual PPAR agonists. Lanifibranor has received Breakthrough Therapy and Fast Track designations from the FDA for MASH/NASH. It is currently in Phase III clinical trials for NASH/fibrosis and has been investigated in other indications such as type 2 diabetes mellitus and idiopathic pulmonary fibrosis[1][4][6].
- Other names
- LanifbranorLibfranor
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on lanifibranor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lanifibranor.